On Friday, the pharmaceutical industry launched a seven-figure national ad campaign urging lawmakers to compel PBMs to pass rebates directly to consumers at the pharmacy counter. Called point-of-sale rebates, PBMs and others argue that this would ultimately raise premiums.
While pharmaceutical companies were the main target of Democrats' efforts to reduce the cost of drugs, PBMs, which spent $5.9 million on lobbying in the first nine months of this year, a 20 percent increase over the same period in 2020, emerged largely unscathed in the House version. “Chairman Wyden is the champion on this issue,” said James Gelfand, the executive vice president of public affairs at the ERISA Industry Committee, which represents the employee benefits interests of the nation’s largest employers. “So it’d be crazy to think that he’s not right now considering, ‘What else can I do in this space?’”Sen. Ron Wyden speaks to reporters as he leaves the Senate chamber at the Capitol in Washington, D.C.
“There is this sentiment around some stakeholders that they believe, ‘Well, gee, if one part of the drug supply chain is going to be impacted by this legislation, then the PBM industry needs to give its pound of flesh as well,’” he said. “And I don't know that that's a very thoughtful consideration to put into policy decisions.”
Get rid of special “safe harbors” in federal antikickback laws which enable PBM’s to collect Rx rebates and then not share the Rx rebates with the patients who are prescribed the heavily-rebated Rx drugs.
Written by a PBM marketing firm
If they don’t want to be seen as villains they can easily remedy that by making insulin free
It is not Democrats, it is just Joe Manchin and Kyrsten Sinema. Democrats as a whole want to bring down drug prices and healthcare costs.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: DEADLINE - 🏆 109. / 63 Read more »
Source: Cosmopolitan - 🏆 725. / 51 Read more »
Source: TODAYshow - 🏆 389. / 55 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: ABC - 🏆 471. / 51 Read more »